Case Study

How MMS Scaled Biostatistics Expertise to Accelerate a High Priority Vaccine Program

Discover how strategic Functional Service Provision (FSP) helped a global pharma sponsor deliver complex statistical analyses on time without compromising quality.

When tight timelines, interdisciplinary teams, and complex statistical challenges converge, having the right expertise at the right moment becomes mission critical. This case study shows how a leading pharmaceutical company partnered with MMS to rapidly onboard an experienced statistician through a flexible Functional Service Provision (FSP) model.

Designed for clinical operations leaders, biometrics heads, and project owners managing high stakes development programs, this resource reveals how MMS ensures seamless integration, capability expansion, and consistent delivery across global teams.

You’ll learn how our tailored FSP support enabled the sponsor to meet demanding project timelines while enhancing the quality and impact of their vaccine research, ultimately contributing to a publication in The Lancet.

What You’ll Learn:

  • See how MMS rapidly deployed specialized biostatistical expertise to support a complex vaccine development program.
  • Understand how seamless onboarding, GCP ready resources, and IT support accelerate time to impact.
  • Learn how flexible FSP models adapt to evolving timelines, workloads, and global team structures.
  • Discover the real world outcomes including improved cross functional collaboration and high quality deliverables for regulatory submissions.

Created by MMS biometrics experts supporting global sponsors with advanced statistical, programming, and data science leadership across every phase of clinical development.

Access the Full FSP Case Study

How MMS Scaled Biostatistics Expertise to Accelerate a High Priority Vaccine Program
casestudy

How MMS Scaled Biostatistics Expertise to Accelerate a High Priority Vaccine Program

Discover how strategic Functional Service Provision (FSP) helped a global pharma sponsor deliver complex statistical analyses on time without compromising quality.

Suggested For You

case study

July 31st, 2026

Delivering Strategic Biostatistics Support to Enable Phase 2b Funding Decisions

case study

July 8th, 2026

Operating as an Integrated Regulatory Writing and Submission Partner for Small and Mid-Size Pharmaceutical Companies

case study

June 30th, 2026

Turning Regulatory Pressure into a Strategic Partnership: Public Release of Clinical Information (PRCI) for a Large Biotech Organization

case study

December 10th, 2025

From Challenge to Confidence: How MMS Delivered 800+ High-Quality Narratives in Record Time

case study

December 4th, 2025

How MMS Modernized Pulmonary Data Models to Streamline Clinical Analysis and Improve Decision-Making

case study

December 1st, 2025

Expert Support for Regulatory Briefing Books that Strengthen Sponsor Defense Strategies

case study

November 24th, 2025

Regulatory Expertise that Strengthens Global Market Success

case study

November 19th, 2025

How MMS Supported IDMC Operations to Ensure Integrity and Safety in a High Complexity COVID 19 Trial

case study

November 17th, 2025

Strengthen Early Phase Oncology Trials with Expert Biostatistical Support

case study

November 14th, 2025

Transforming Real-World Data into Regulatory-Ready Evidence with KerusCloud®

case study

November 12th, 2025

How One Sponsor Rescued an Underpowered Trial Using Simulation-Guided Design

case study

November 10th, 2025

Evaluating Biomarkers with KerusCloud®: Powering Precision in Early Clinical Decision-Making